WO2020032885A3 - Compositions capsule dans capsule d'étéxilate de dabigatran - Google Patents

Compositions capsule dans capsule d'étéxilate de dabigatran Download PDF

Info

Publication number
WO2020032885A3
WO2020032885A3 PCT/TR2019/050292 TR2019050292W WO2020032885A3 WO 2020032885 A3 WO2020032885 A3 WO 2020032885A3 TR 2019050292 W TR2019050292 W TR 2019050292W WO 2020032885 A3 WO2020032885 A3 WO 2020032885A3
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
dabigatran etexilate
compositions
polymorphs
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050292
Other languages
English (en)
Other versions
WO2020032885A2 (fr
Inventor
Arzu PALANTOKEN
Yildiz Gulkok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2018/06309A external-priority patent/TR201806309A2/tr
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP19848668.0A priority Critical patent/EP3787624A4/fr
Publication of WO2020032885A2 publication Critical patent/WO2020032885A2/fr
Publication of WO2020032885A3 publication Critical patent/WO2020032885A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions capsule dans capsule comprenant de l'étéxilate de dabigatran sous la forme de la base libre ou sous la forme de sels, de polymorphes, de solvates, d'hydrates ou d'esters pharmaceutiquement acceptables de ces derniers et au moins un acide organique, lesdites compositions étant caractérisées en ce que l'une des capsules comprend au moins un revêtement.
PCT/TR2019/050292 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran Ceased WO2020032885A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19848668.0A EP3787624A4 (fr) 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2018/06309 2018-05-04
TR2018/06309A TR201806309A2 (tr) 2017-05-10 2018-05-04 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR201906582 2019-05-03
TR2019/06582 2019-05-03

Publications (2)

Publication Number Publication Date
WO2020032885A2 WO2020032885A2 (fr) 2020-02-13
WO2020032885A3 true WO2020032885A3 (fr) 2020-09-24

Family

ID=69414341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050292 Ceased WO2020032885A2 (fr) 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran

Country Status (2)

Country Link
EP (1) EP3787624A4 (fr)
WO (1) WO2020032885A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577067B (zh) * 2021-06-03 2023-08-15 北京福元医药股份有限公司 一种甲磺酸达比加群酯药物制剂
CN120938941A (zh) * 2025-10-17 2025-11-14 杭州高成生物营养技术有限公司 一种酒石酸微丸及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162492A1 (fr) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Noyau comprimé comprenant des acides organiques pour une composition pharmaceutique
WO2013124340A1 (fr) * 2012-02-21 2013-08-29 Laboratorios Del Dr. Esteve, S.A. Compositions pharmaceutiques orales de dabigatran étexilate
US20150157618A1 (en) * 2013-11-26 2015-06-11 Chandrashekhar Kandi Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001272645A1 (en) * 2000-07-20 2002-02-05 Mw Encap Limited Delivery device
PL2588090T3 (pl) * 2010-07-01 2017-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
EP2929884A1 (fr) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et antagonistes du récepteur de h2
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
WO2016142821A2 (fr) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions contenant un inhibiteur de la thrombine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162492A1 (fr) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Noyau comprimé comprenant des acides organiques pour une composition pharmaceutique
WO2013124340A1 (fr) * 2012-02-21 2013-08-29 Laboratorios Del Dr. Esteve, S.A. Compositions pharmaceutiques orales de dabigatran étexilate
US20150157618A1 (en) * 2013-11-26 2015-06-11 Chandrashekhar Kandi Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof

Also Published As

Publication number Publication date
EP3787624A4 (fr) 2022-03-30
WO2020032885A2 (fr) 2020-02-13
EP3787624A2 (fr) 2021-03-10

Similar Documents

Publication Publication Date Title
JOP20200122A1 (ar) مركبات مفيدة لتثبيط cdk7
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
PH12019501639A1 (en) Jaki selective inhibitors
AU2018271990A1 (en) Covalent inhibitors of KRAS
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
WO2015200680A8 (fr) Inhibiteurs de prmt5 et leurs utilisations
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
MY210123A (en) Tlr7/8 antagonists and uses thereof
MY194262A (en) Inhibitors of ret
WO2016164675A8 (fr) Composés quinazoline substitués et leurs procédés d'utilisation
IN2013CH05441A (fr)
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
IN2014MN02245A (fr)
WO2020032885A3 (fr) Compositions capsule dans capsule d'étéxilate de dabigatran
WO2016142821A3 (fr) Compositions contenant un inhibiteur de la thrombine
EP4582145A3 (fr) Formes à l'état solide de citrate d'ixazomib
WO2019004980A3 (fr) Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
WO2019240698A3 (fr) Compositoins pharmaceutiques orales comprenant du posaconazole
WO2016069542A3 (fr) Composés de lactone, leurs procédés de préparation et d'utilisation
IN2014MU00859A (fr)
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
PH12020500385A1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
TR201722323A2 (tr) Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19848668

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019848668

Country of ref document: EP

Effective date: 20201204